ZLCS Key Stats
- ZALICUS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Hol... Jun 6
- Zalicus Advancing Clinical Development of Z944, Its Novel, Oral, T-Type Calcium ... Jun 4
- ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 4
- Zalicus to Present at the Jefferies 2013 Global Healthcare Conference Business Wire May 29
- Zalicus Awaiting Data On Potential New Pain Medication May 23
- ZALICUS INC. Financials May 10
- Zalicus Presents Data on Novel, Oral, N- and T-Type Calcium Channel Blockers for... May 10
- ZALICUS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 10
- Zalicus (ZLCS) Enters $25M Committed Funding Agreement Street Insider May 8
- Zalicus Secures New $25 Million Funding Commitment from Lincoln Park Capital Business Wire May 8
ZLCS Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Zalicus is down 57.23% over the last year vs S&P 500 Total Return up 25.82%, Vical down 0.97%, and ARCA biopharma down 56.19%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for ZLCS
Pro Strategies Featuring ZLCS
Did Zalicus make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.